Human Immunodeficiency Virus 
Welcome,         Profile    Billing    Logout  

503 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Human Immunodeficiency Virus
2018-003481-13: An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease -The Late Presenter Treatment Optimisation Study (LAPTOP)-

Not yet recruiting
3
440
Europe
Biktarvy, Symtuza, [J05AR], [J05AR22], Film-coated tablet, Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences Inc, Janssen Pharmaceutica NV, Gilead Sciences, Inc.,
Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus), A virus that damages patient's immune system causing the patient difficulty to fight off infections and diseases., Diseases [C] - Virus Diseases [C02]
 
 
DISCOVER, NCT02842086 / 2016-001399-31: Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Active, not recruiting
3
5399
Europe, Canada, US
F/TAF, Descovy®, F/TDF, Truvada®, F/TAF Placebo, F/TDF Placebo
Gilead Sciences
Pre-Exposure Prophylaxis of HIV-1 Infection
01/19
09/27
ATLAS-2M, NCT03299049 / 2017-002946-62: Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Active, not recruiting
3
1049
Europe, Canada, US, RoW
Cabotegravir Tablets, Rilpivirine Tablets, Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
ViiV Healthcare, Janssen Research and Development
HIV Infections
06/19
12/26
2018-004885-32: THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/LAMIVUDINE/ABACAVIR (D/L/A) TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (B/F/TAF) IN PATIENTS WITH SUPPRESSED VIRAL LOAD ON NEUROPSYCHIATRIC SIDE EFFECTS AND NEUROCOGNITIVE FUNCTION L’IMPATTO DEL PASSAGGIO DA DOLUTEGRAVIR/LAMIVUDINA/ABACAVIR (D/L/A) A BICTEGRAVIR/EMTRICITABINA/TENOFOVIR ALAFENAMIDE (B/F/TAF) NEI PAZIENTI IN TERAPIA ANTIRETROVIRALE CON HIVRNA SOPPRESSO SUGLI EVENTI AVVERSI NEUROPSICHIATRICI E SULLE FUNZIONI NEUROCOGNITIVE

Not yet recruiting
3
100
Europe
bictegravir/emtricitabina/tenofovir alafenamide, TRIUMEQ, [GS-9883-01], [dolutegravir/abacavir/lamivudina], Tablet, BIKTARVY, TRIUMEQ
AZIENDA OSPEDALIERA UNIVERSITARIA SENESE, Gilead Sciences
HIV-1 infection Infezione da HIV-1, Human immunodeficiency virus type 1 (HIV-1) infection Infezione da virus dell'immunodeficienza umana acquisita 1 (HIV-1), Diseases [C] - Virus Diseases [C02]
 
 
2018-001730-18: Phase III, random, one-site, pilot, open, parallell group trial for evaluating the eficacy and safety of electrocoagulation vs topic sinecatechins vs topic cidofovir in the High-grade anal intraepithelial neoplasia in HIV homosexuals males Ensayo clínico fase III, aleatorizado, unicéntrico, piloto, abierto, de grupos paralelos para valorar la eficacia y seguridad de la electrocoagulación vs sinecatequinas tópicas vs cidofovir tópico en el tratamiento de la neoplasia intraepitelial anal de alto grado, en varones que tienen sexo con hombres con infección por VIH (TreatAIN).

Not yet recruiting
3
108
Europe
Veregen, Cidofovir, Ointment, Cream, Veregen
Fundación Hospital Vall d'Hebron- Institut de Recerca, Instituto de Salud Carlos III
High-grade anal intraepithelial neoplasia Neoplasia intraepitelial anal de alto grado, High-grade anal intraepithelial neoplasia Neoplasia intraepitelial anal de alto grado, Diseases [C] - Virus Diseases [C02]
 
 
2018-003666-13: A clinical study to evaluate the effectiveness of a vaccine regimen consisting of Ad26.Mos4.HIV and a combination of adjuvanted Clade C gp140 and Mosaic gp140 to prevent HIV-1 infection among cis-gender men and transgender individuals who have sex with cis-gender men and/or transgender individuals Estudio clínico para evaluar la efectividad de un régimen de vacuna que consiste en Ad26.Mos4.HIV y una combinación de Clade C gp140 y el Mosaico gp140 para prevenir la infección por VIH-1 entre hombres cis-género y personas transgénero que tienen sexo con hombres cis-género y/o personas transgénero.

Ongoing
3
3800
Europe
Ad26.Mos4.HIV, Adjuvanted Clade C and Mosaic gp140 HIV Bivalent Vaccine, Recombinant, JNJ-65184340, Solution for injection, Suspension for injection
Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V., National Institute of Allergy and Infectious Diseases, JANSSEN CILAG SPA
Prevention of HIV-1 Infection Prevención de la infección por el VIH-1, Prevention of HIV-1 Infection Prevención de la infección por el VIH-1, Diseases [C] - Virus Diseases [C02]
 
 
2019-004241-32: Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study) Switching precoce a DOlutegravir/LAmivudine dopo soppressione virologica

Ongoing
3
440
Europe
DOVATO, [DTG/3TC], Film-coated tablet, Dovato
SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI, ViiV Healthcare s.r.l.
HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL Pazienti affetti da HIV-1 in trattamento da meno di 18 mesi con un regime di prima linea a tre farmaci contenente INSTI che hanno raggiunto la soppressione virologica con HIV-1 RNA <50 copie/mL, HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL pazienti affetti da HIV-1 in trattamento da meno di 18 mesi con un regime di prima linea a tre farmaci contenente INSTI che hanno raggiunto la soppressione virologica con HIV-1 RNA <50 copie/mL, Diseases [C] - Virus Diseases [C02]
 
 
2017-004322-15: A study of the safety, tolerability and immune response of a nine-valent human papillomavirus (HPV) vaccine (Gardasil®9) in HIV-infected patients (18 to 45 years of age) and solid organ transplant recipients (18 to 55 years of age). Een klinisch onderzoek om de veiligheid, verdraagbaarheid en immuun antwoord van GARDASIL®9 (een 9-waardig humaan papillomavirus [HPV] vaccin) te bestuderen bij HIV patiënten (18 tot 45 jaar) en transplantpatiënten (18 tot 55 jaar).

Not yet recruiting
3
310
Europe
Gardasil9, Solution for injection in pre-filled syringe, Gardasil9
UZ Leuven, MSD Belgium BVBA
Immune response to HPV vaccination in HIV-patients and Solid Organ Transplant patients Immuunantwoord na HPV vaccinatie bij HIV patiënten en Vaste Orgaan Transplantpatiënten, Infections with human papillomavirus Infecties met humaan papillomavirus, Body processes [G] - Immune system processes [G12]
 
 
NCT00980538 / 2009-013126-16: TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

Active, not recruiting
3
180
Europe, Canada, US, RoW
Etravirine
Janssen Sciences Ireland UC
HIV Infections, HIV-1
11/20
01/32
ANCHOR, NCT02135419: Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Active, not recruiting
3
4446
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, Efudex, infrared photocoagulation therapy, infrared coagulation, IRC, thermal ablation therapy, laser therapy, therapy, laser, clinical observation, observation, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, University of California, San Francisco, University of Arizona
Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
08/21
03/24
MK-8591A-018, NCT04223791 / 2019-000587-23: Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
643
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL, Placebo to MK-8591A
Merck Sharp & Dohme LLC
HIV Infection
08/21
02/25
MK-8591A-017, NCT04223778 / 2019-000586-20: Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1

Active, not recruiting
3
672
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, ART
Merck Sharp & Dohme LLC
HIV Infection
09/21
11/24
NCT03682848: Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

Active, not recruiting
3
32
RoW
DTG + 3TC FDC
ViiV Healthcare
HIV Infections
12/21
02/24
2021-002565-17: Study to evaluate virological efficacy, safety tolerability of the to 2-drug therapy with DTG/3TC FDC or the antiretroviral tenofovir (TAF or TDF) -containing regimen (T-CR) in HIV-1 infected virologically suppressed women Studio che mira a valutare l'efficacia virologica, la tollerabilità di sicurezza della terapia a 2 farmaci con DTG/3TC FDC o della prosecuzione del regime in corso con l’antiretrovirale tenofovir (TAF o TDF) in donne infette da HIV-1 virologicamente soppresse

Not yet recruiting
3
290
Europe
Dolutegravir (DTG) - lamivudine (3TC), [DTG/3TC], Film-coated tablet, DOVATO - 50 MG / 300 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, viiv healthcare
HIV-1-infected adult women of >18 years of age, without previous virologic failure, currently receiving an effective (HIV-RNA < 50 copies/ml) triple-drug cART, containing tenofovir (TAF or TDF) in the regimen Donne adulte con infezione da HIV-1 di età> 18 anni, senza precedente fallimento virologico, che attualmente ricevono una terapia cART a tre farmaci efficace (HIV-RNA <50 copie/ml), con tenofovir (TAF o TDF) nel regime, Women who are virologically suppressed without previous virological failure currently receiving tenofovir (TAF or TDF) in the regimen Donne con soppressione virologica in assenza di precedente fallimento virologico che attualmente ricevono una terapia con tenofovir (TAF o TDF) nel regime, Diseases [C] - Virus Diseases [C02]
 
 
NCT03547908 / 2018-000926-79: Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

Completed
3
244
Europe, Japan, US, RoW
B/F/TAF, Biktarvy®, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Truvada®, Placebo to match B/F/TAF
Gilead Sciences
HIV-1/HBV Co-Infection
02/22
03/24
CARISEL, NCT04399551 / 2020-000424-19: A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries

Completed
3
437
Europe
CAB OLI, CAB LA, RPV OLI, RPV LA, Continuous Quality Improvement (CQI) calls
ViiV Healthcare, Janssen Pharmaceuticals
HIV Infections
03/22
03/23
NCT04303598: Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients

Not yet recruiting
3
720
RoW
FNC, Azvudine, 3TC, Lamivudine, TDF, Tenofovir Fumarate, EFV, Efavirenz, FNC placebo, Azvudine placebo, 3TC placebo, Lamivudine placebo
HeNan Sincere Biotech Co., Ltd
HIV-infection/Aids
05/22
08/22
SOLAR, NCT04542070 / 2020-002623-11: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Completed
3
687
Europe, Canada, Japan, US, RoW
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
ViiV Healthcare, Janssen, LP
HIV Infections
07/22
04/23
NCT05896761: A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants

Completed
3
118
Europe, Canada, US, RoW
Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
ViiV Healthcare, Janssen Research and Development
Human Immunodeficiency Virus Type 1 (HIV-1)
08/22
08/22
2021-006710-36: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults Living With HIV

Not yet recruiting
3
300
Europe
Pneumococcal 21-Valent Conjugate Vaccine, V116, Solution for injection in pre-filled syringe, Suspension for injection in pre-filled syringe, PNEUMOVAX® 23 (pneumococcal vaccine polyvalent), VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine)
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pneumococcal disease, Pneumococcal disease, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT03913195: Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

Completed
3
46
US
ibalizumab-uiyk, Trogarzo
TaiMed Biologics Inc., Westat
HIV-1-infection
10/22
10/22
MK-8591A-020, NCT04233879 / 2019-000590-23: Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Active, not recruiting
3
599
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir, BIC/FTC/TAF, Bictegravir/emtricitabine/tenofovir alafenamide, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
03/25
MK-8591A-019, NCT04233216 / 2019-000588-26: Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Completed
3
35
Europe, Canada, Japan, US, RoW
ISL, Islatravir, MK-8591, DOR, Doravirine, MK-1439, DOR/ISL, Doravirine/Islatravir, MK-8591A, Placebo to ISL, Placebo to DOR
Merck Sharp & Dohme LLC
HIV-1 Infection
11/22
11/23
PrEP-PP PK, NCT04937881: PK of TAF and TDF for PrEP in Pregnant and Postpartum Women

Completed
3
50
RoW
Tenofovir alafenamide, TAF, Tenofovir Disoproxil Fumarate, TDF or Truvada
University of California, Los Angeles, University of Cape Town, Desmond Tutu HIV Foundation, Gilead Sciences
Hiv
04/23
09/23
NCT05896748: Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

Completed
3
93
Europe, Canada, Japan, US, RoW
Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA)
ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline
Human Immunodeficiency Virus Type 1 (HIV-1)
04/23
09/23
2020-001426-57: A study to compare whether giving two rather than three anti-HIV medicines daily to children and young people, aged between 2 and 15 years is assafe and effective in controlling their HIV infection Ensayo para comparar si la administración de dos en vez de tres fármacos anti-VIH diariamente en niños y pacientes jóvenes entre 2 y 15 años es tan segura y efectiva en el control de su infección por VIH.

Not yet recruiting
3
370
Europe
DTG/3TC DT, Dovato, Tivicay PD, Tivicay, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy, Dolutegravir, Dispersible tablet, Film-coated tablet, Capsule, hard, Dovato, TIVICAY PD, TIVICAY, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy
Fondazione Penta Onlus, ViiV Healthcare UK Limited
HIV Infection Infección por VIH, HIV Infection Infección por VIH, Diseases [C] - Virus Diseases [C02]
 
 
DAWN, NCT05457530: Doravirine and Weight Gain in Antiretroviral Naive

Withdrawn
3
150
US
DOR/3TC/TDF, Delstrigo, DOR + FTC/TAF, Pifeltro + Descovy, BIC/FTC/TAF, Biktarvy
Prism Health North Texas, Merck Sharp & Dohme LLC
Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
05/23
05/23
NCT04416906: A Test and Treat Strategy in New HIV Diagnosis.

Completed
3
100
Europe
Biktarvy
Judit Pich Martínez, Gilead Sciences
HIV-1-infection
05/23
05/23
STRIDE-7, NCT05393037: Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, )

Completed
3
313
Europe, US, RoW
V116, Pneumococcal 21-valent Conjugate Vaccine, Placebo, PCV15, VAXNEUVANCE™;, PPSV23, PNEUMOVAX™23
Merck Sharp & Dohme LLC
Pneumococcal Disease
07/23
01/24
Impower-022, NCT04644029 / 2021-001289-39: Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Active, not recruiting
3
730
US, RoW
Islatravir, MK-8591, Placebo to FTC/TDF, FTC/TDF, TRUVADA™, Emtricitabine/Tenofovir disoproxil, Emtricitabine/Tenofovir disoproxil fumarate, Placebo to ISL
Merck Sharp & Dohme LLC
HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis
07/23
07/24
BIC-T&T, NCT04653194 / 2019-003208-11: Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Completed
3
36
Europe
Biktarvy, Symtuza
Chelsea and Westminster NHS Foundation Trust, Imperial College London, Gilead Sciences
Human Immunodeficiency Virus
07/23
07/23
Impower-024, NCT04652700 / 2020-003309-79: Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Completed
3
494
Europe, Japan, US, RoW
ISL, MK-8591, FTC/TDF, Truvada, Emtricitabine/Tenofovir Disoproxil Fumarate, FTC/TAF, Descovy, Emtricitabine/Tenofovir Alafenamide, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Merck Sharp & Dohme LLC
HIV Preexposure Prophylaxis
08/23
08/23
MOSAICO, NCT03964415 / 2018-003666-13: A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

Hourglass Jan 2023 - Dec 2023 : Efficacy data from MOSAICO trial for prophylaxis of HIV-1
Completed
3
3900
Europe, US, RoW
Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine, Placebo
Janssen Vaccines & Prevention B.V., Janssen Vaccines & Prevention B.V., National Institute of Allergy and Infectious Diseases, JANSSEN CILAG SPA
Healthy
08/23
08/23
REPRIEVE, NCT02344290: Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Completed
3
7769
Europe, Canada, US, RoW
Pitavastatin, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), National Heart, Lung, and Blood Institute (NHLBI), Kowa Pharmaceuticals America, Inc., Gilead Sciences, Massachusetts General Hospital, NEAT ID Foundation
HIV Infections, Cardiovascular Diseases
08/23
08/23
PREGNANT, NCT04808973: DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women

Completed
3
20
RoW
Dolutegravir plus lamivudine in a FDC
Fundação Bahiana de Infectologia, GlaxoSmithKline
HIV Infections, Pregnancy Related, Mother to Child Transmission
08/23
09/23
AXIS, NCT06138600: Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa

Active, not recruiting
3
200
RoW
Cabotegravir Injection [Apretude], Apretude, Tenofovir disoproxil fumarate / emtricitabine (or lamivudine), Tenemine
University of Witwatersrand, South Africa, ViiV Healthcare
HIV Infections
10/25
01/26
NCT02059499: Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions

Completed
3
91
US
imiquimod, Aldara, IMQ, R 837, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, questionnaire administration, laboratory biomarker analysis
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas
Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection
12/23
04/24
MORISOT, NCT06325657: A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants

Recruiting
3
330
RoW
RSVpreF vaccine, Placebp
Pfizer
Respiratory Syncytial Virus
10/26
10/26
ARTISTRY-2, NCT06333808: Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

Recruiting
3
546
Canada, Japan, US, RoW
Bictegravir, GS-9883, Lenacapavir, GS-6207, B/F/TAF, Biktarvy ®, Placebo to match B/F/TAF, Placebo to match BIC/LEN
Gilead Sciences
HIV-1-infection
12/25
12/29
ELDORADO, NCT06203132: DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

Not yet recruiting
3
610
Europe, RoW
Doravirine + tenofovir DF + lamivudine, Delstrigo, Dolutegravir + tenofovir DF + lamivudine or emtricitabine
ANRS, Emerging Infectious Diseases, MSD France
HIV-1-infection
04/26
04/27
PALISADE, NCT06134362: Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Not yet recruiting
3
3500
RoW
CAB LA, Apretude, CAB LA for PrEP
ViiV Healthcare, GlaxoSmithKline, PPD
HIV Infections
06/27
06/27
PrEPSteps, NCT03512418: Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users

Completed
3
36
US
PrEPsteps, Digital pill, Truvada
Brigham and Women's Hospital, Gilead Sciences, The Fenway Institute
HIV Infections, Substance Use Disorders
04/24
04/24
NCT03696160: The Late Presenter Treatment Optimisation Study

Active, not recruiting
3
447
Europe
Biktarvy, Symtuza
NEAT ID Foundation, Gilead Sciences, Janssen Pharmaceuticals
HIV/AIDS
06/24
06/24
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Active, not recruiting
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
07/24
07/24
NCT06281119: Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

Not yet recruiting
3
450
RoW
Cervavac as three dose regimen, Cervavac as two dose regimen, Gardasil as three dose regimen
Serum Institute of India Pvt. Ltd., Bill and Melinda Gates Foundation
Human Papillomavirus Infection
12/25
05/26
Sungura, NCT06444620: B/F/TAF to DTG/3TC Switch Study

Not yet recruiting
3
240
RoW
DTG/3TC, Avridela
University of Nairobi, ViiV Healthcare, Mylan Laboratories
HIV-1-infection
06/25
06/26
SmartSteps, NCT05378399: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder

Recruiting
3
40
US
Descovy or Truvada, ID-Cap System, digital pill, Beiwe
Brigham and Women's Hospital, Gilead Sciences, The Fenway Institute
HIV Infections, Substance Use, Adherence, Medication, Adherence, Treatment
06/24
08/24
PURPOSE 1, NCT04994509: Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection

Active, not recruiting
3
5368
RoW
Oral Lenacapavir (LEN), GS-6207, Subcutaneous (SC) Lenacapavir (LEN), F/TAF, Descovy®, F/TDF, Truvada®, Placebo SC LEN, PTM Oral LEN, PTM F/TAF, PTM F/TDF
Gilead Sciences
Pre-Exposure Prophylaxis of HIV Infection
09/24
07/27
ALADDIN, NCT06468995: Antiviral Long Acting Drugs Landing in People Living With HIV

Not yet recruiting
3
120
Europe
Surveys completion, Home administration of CAB+RPV, Hospital administration of CAB+RPV
IRCCS San Raffaele, GlaxoSmithKline
HIV, Antiviral Agents
03/26
11/26
NCT03016533: Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Active, not recruiting
3
101
US, RoW
Dolutegravir film-coated tablets, Dolutegravir film-coated dispersible tablets, ABC/DTG/3TC immediate release tablets, ABC/DTG/3TC film-coated dispersible tablets
ViiV Healthcare
HIV Infections
07/24
07/24
MK-8591A-051, NCT05631093: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART)

Active, not recruiting
3
501
Europe, Canada, Japan, US, RoW
ART, DOR/ISL, MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/24
10/25
MK-8591A-052, NCT05630755: A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Active, not recruiting
3
501
Europe, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
Merck Sharp & Dohme LLC
HIV-1 Infection
11/24
10/25
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Recruiting
3
350
US
Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
06/25
12/26
PURPOSE 2, NCT04925752: Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

Active, not recruiting
3
3295
US, RoW
Oral Lenacapavir (LEN), GS-6207, F/TDF, Truvada®, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only)
Gilead Sciences
Pre-Exposure Prophylaxis of HIV Infection
01/25
04/27
NCT06028841: A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)

Recruiting
3
75
RoW
VLA1553
Valneva Austria GmbH
Chikungunya Virus Infection
01/25
09/25
MODERATO, NCT04022967: ANRS 12372 Study

Active, not recruiting
3
480
RoW
dolutegravir, atazanavir boosted with ritonavir, tenofovir + lamivudine +efavirenz or dolutegravir + lamivudine + tenofovir, Lamivudine
ANRS, Emerging Infectious Diseases, Mylan Laboratories
HIV-1-infection
02/25
02/25
LATA, NCT05154747: Long-Acting Treatment in Adolescents

Active, not recruiting
3
476
RoW
Cabotegravir, Rilpivirine Drug Combination, CAB, RPV, TLD
University College, London, European and Developing Countries Clinical Trials Partnership (EDCTP), Janssen-Cilag Ltd., ViiV Healthcare, Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands., London School of Hygiene and Tropical Medicine, MRC/UVRI and LSHTM Uganda Research Unit, Africa Health Research Institute, PENTA Foundation, University of York
Hiv, HIV Infections, HIV-1-infection, Paediatric Human Immunodeficiency Virus Infection
03/25
03/26
EYEWITNESS, NCT05911360: A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

Active, not recruiting
3
206
Europe, Canada, US, RoW
DTG/3TC
ViiV Healthcare
HIV, HIV Infections
02/25
02/26
COVENANT, NCT03284866: HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV

Active, not recruiting
3
536
RoW
Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine, Recombinant HPV 9-valent Vaccine, Saline, Sodium Chloride 0.9%
AIDS Malignancy Consortium, National Cancer Institute (NCI), University of Arkansas, AIDS and Cancer Specimen Resource, Merck Sharp & Dohme LLC, The Emmes Company, LLC, University of California, Los Angeles
AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection
12/24
03/27
VOGUE, NCT05979311: A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

Not yet recruiting
3
412
Europe, Japan, RoW
Dolutegravir, Lamivudine, Bictegravir, Emtricitabine, Tenofovir alafenamide
ViiV Healthcare
HIV, HIV Infections
09/25
08/26
VOLITION, NCT05917509: A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruiting
3
171
Europe, Canada, US, RoW
DTG/3TC, Dovato, Cabotegravir (CAB) LA, Vocabria, Rilpivirine (RPV) LA, Rekambys
ViiV Healthcare, GlaxoSmithKline, PPD
HIV Infections
08/25
08/26
MK-8591A-033, NCT04776252 / 2020-001191-14: Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

Active, not recruiting
3
2000
Europe, Canada, Japan, US, RoW
MK-8591A
Merck Sharp & Dohme LLC
HIV-1 Infection
10/27
10/27
NCT05705349: DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF
Merck Sharp & Dohme LLC
HIV-1 Infection
10/25
11/26
NCT03149211: To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

Withdrawn
3
520
RoW
UB-421, dB4C7 mAb, current standard HAART treatment
United BioPharma
HIV-1 Infection
12/25
12/25
MK-8591A-054, NCT05766501: A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
DOR/ISL, MK-8591A, Doravirine/islatravir
Merck Sharp & Dohme LLC
HIV Infection
01/26
01/26
NCT04255849: Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV

Active, not recruiting
3
700
US, RoW
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Saline Placebo
Weill Medical College of Cornell University, H. Lee Moffitt Cancer Center and Research Institute, University of Sao Paulo, University of Puerto Rico, Mexican National Institute of Public Health, National Cancer Institute (NCI), Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection
04/26
04/26
Opti-DOR, NCT05924438: A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy

Recruiting
3
600
RoW
Delstrigo, KOCITAF
Professor Francois Venter, Africa Health Research Institute, Merck Sharp & Dohme LLC
HIV-1-infection
06/26
06/26
NCT04406727: UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

Not yet recruiting
3
50
NA
UB-421, Antiretroviral (ARV)
United BioPharma
HIV-1 Infection
06/26
06/26
SimpPrEP, NCT05813964: Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

Recruiting
3
524
Europe, RoW
TDF/FTC 300mg/200mg fixed-dose combination tablets, Truvada, TAF/FTC 25mg/200mg fixed-dose combination tablets, Descovy
ANRS, Emerging Infectious Diseases, Chiang Mai University, Thailand, Ministry of Health, Thailand, Assistance Publique - Hôpitaux de Paris, FRANCE, Gilead Sciences
HIV/AIDS
10/26
05/27
MTBVACN3, NCT04975178: Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

Recruiting
3
7120
RoW
MTBVAC, BCG
Biofabri, S.L, TuBerculosis Vaccine Initiative, University of Cape Town, Institut Pasteur de Madagascar, Biomedical Research Center EPLS, Universidad de Zaragoza, University of Stellenbosch, University of KwaZulu, Wits Health Consortium (Pty) Ltd
Tuberculosis
06/28
09/29
AAHIV, NCT00796263: Antiretroviral Therapy for Acute and Chronic HIV Infection

Recruiting
3
722
RoW
HAART, Kivexa, Tivicay
South East Asia Research Collaboration with Hawaii, Thai Red Cross AIDS Research Centre, Pfizer, Gilead Sciences, Merck Sharp & Dohme LLC, ViiV Healthcare
Acute HIV Infection, Chronic HIV Infection
06/33
06/33
NCT01338038: A Trial of Lopinavir/Ritonavir Dosed According to the Who Pediatric Weight Band Dosing Guidelines

Recruiting
2/3
94
US, RoW
Lopinavir/ritonavir (LPV/r), Kaletra
International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Abbott
HIV Infection
12/13
01/14
NCT02285114 / 2015-001339-19: Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen

Active, not recruiting
2/3
41
US, RoW
F/TAF, 3rd ARV agent, Boosted PIs
Gilead Sciences
HIV-1
11/19
12/24
2019-003814-16: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance Estudio de fase 2/3 para evaluar la seguridad y eficacia del inhibidor de la cápside de acción prolongada GS-6207 en combinación con un tratamiento de base optimizado en pacientes con infección por VIH-1 altamente tratados y con multirresistencia a fármacos

Not yet recruiting
2/3
100
Europe
GS-6207, GS-6207, Tablet, Solution for injection
Gilead Sciences, Inc., GILEAD SCIENCES INCORPORATED, Gilead Sciences, Inc.
Human Immunodeficiency Virus (HIV-1) Infection Infección por el virus de la inmunodeficiencia humana (HIV-1), Human Immunodeficiency Virus (HIV-1) Infection Infección por el virus de la inmunodeficiencia humana (HIV-1), Diseases [C] - Virus Diseases [C02]
 
 
NCT01854775 / 2013-002780-26: Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

Active, not recruiting
2/3
129
US, RoW
E/C/F/TAF, Genvoya®, E/C/F/TAF (Low Dose)
Gilead Sciences
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
05/20
12/24
HPTN 083, NCT02720094: Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Active, not recruiting
2/3
4570
US, RoW
Cabotegravir Oral Tablet, Oral cabotegravir, TDF/FTC tablets, Truvada, Placebo for TDF/FTC tablets, Placebo for Truvada, Placebo for cabotegravir oral tablet, Placebo for oral cabotegravir, CAB LA, Long acting cabotegravir, Injectable cabotegravir, Placebo for CAB LA, Placebo for long acting cabotegravir
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Gilead Sciences
HIV Infections
05/20
07/24
CAPELLA, NCT04150068: Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

Active, not recruiting
2/3
72
Europe, Canada, Japan, US, RoW
Oral Lenacapavir, Sunlenca®, GS-6207, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
Gilead Sciences
HIV-1-infection
10/20
12/25
NCT04500678: Impact of Metformin on Immuno-virologic Parameters in HIV

Recruiting
2/3
38
US
Metformin
University of Hawaii, Merck Sharp & Dohme Corp.
HIV/AIDS
02/22
12/22
NCT02990858: An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study

Active, not recruiting
2/3
44
NA
PRO 140 SC injections
CytoDyn, Inc.
Hiv, Human Immunodeficiency Virus
06/22
08/22
NCT03902522: PRO 140 in Treatment-Experienced HIV-1 Subjects

Active, not recruiting
2/3
25
US
PRO 140, Leronlimab
CytoDyn, Inc.
HIV-1-infection
07/22
08/22
PRO 140_CD03 Extension, NCT05271370: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

Active, not recruiting
2/3
56
US
PRO 140 350, PRO 140 525, PRO 140 700
CytoDyn, Inc.
HIV-1-infection
12/22
04/23
NCT05204394: Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy

Not yet recruiting
2/3
438
RoW
VM-1500A-LAI, VM-1500A, Depulfavirine, Standard of Care, SoC
Viriom
HIV-1-infection
09/23
10/23
NCT02881320 / 2016-002345-39: Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Recruiting
2/3
170
US, RoW
B/F/TAF (Adult Strength), Biktarvy®, GS-9883/F/TAF, B/F/TAF (Low Dose), B/F/TAF (TOS)
Gilead Sciences
HIV-1 Infection
06/24
12/24
NCT04742491: Pre-Exposure Prophylaxis for Transgender Women in the US and South America

Active, not recruiting
2/3
307
US, RoW
Immediate Intervention Arm Truvada in the US, Truvada, Deferred Intervention Arm Truvada in the US, Immediate Intervention Arm Truvada in Brazil, Deferred Intervention Arm Truvada in Brazil, Immediate Intervention Arm Descovy in the US, Descovy, Deferred Intervention Arm Descovy in the US
HIV Prevention Trials Network, Gilead Sciences
HIV Prevention
09/24
09/24
NCT05140954: The Women TAF-FTC Benchmark Study

Completed
2/3
54
RoW
co-formulated 25mg TAF/ 200mg FTC, Descovy
University of Washington, Kenya Medical Research Institute, University of Colorado, Denver, Gilead Sciences
HIV Infections
12/23
12/23
NCT02016924 / 2013-001402-28: Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Recruiting
2/3
130
Europe, US, RoW
ATV, Reyataz®, DRV, Prezista®, Cobicistat, GS-9350, Tybost®, BR, F/TAF, Descovy®, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Gilead Sciences
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
06/25
03/27
ARTISTRY-1, NCT05502341: Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

Recruiting
2/3
671
Europe, Canada, Japan, US, RoW
Bictegravir, GS-9883, Lenacapavir, GS-6207, BIC/LEN FDC, Stable Baseline Regimen
Gilead Sciences
HIV-1-infection
01/26
11/28
NCT02859961: Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Active, not recruiting
2b
556
US
PRO 140 (350 mg), Leronlimab, PRO 140 (525 mg), PRO 140 (700 mg)
CytoDyn, Inc.
HIV
09/20
06/22
NCT05005156: Phase IIb Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Adults 18 Years of Age and Older.

Recruiting
2b
876
RoW
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV)
Fundación Huésped, Canadian Center for Vaccinology, CanSino Biologics Inc., Hospital Fernandez
Covid19
09/22
09/22
PrEPVacc, NCT04066881: A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

Enrolling by invitation
2b
1668
RoW
Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Vaccine Group C: Saline placebo (weeks 0,4,24,48), Control PrEP:TDF/FTC once daily (weeks 0-26), Truvada, Experimental PrEP:TAF/FTC once daily (weeks 0-26), Descovy
MRC/UVRI and LSHTM Uganda Research Unit, Imperial College London, University College, London, International AIDS Vaccine Initiative, EuroVacc Foundation, Medical Research Council, South Africa, National Institute for Medical Research, Tanzania, Muhimbili University of Health and Allied Sciences, Instituto Nacional de Saúde, Mozambique, Ludwig-Maximilians - University of Munich, King's College London, Centre Hospitalier Universitaire Vaudois, Karolinska Institutet, CONRAD, Gilead Sciences
HIV Infections
12/24
12/24
NCT04003103: Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

Completed
2a
242
US, RoW
Islatravir, MK-8591, Placebo
Merck Sharp & Dohme LLC
HIV-1 Infection
03/22
11/22
AELIX-003, NCT04364035: Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

Completed
2a
50
Europe
ChAdOx1.HTI, MVA.HTI, GS-9620, Vesatolimod, Placebo, Placebo Oral Tablet, N/H
Aelix Therapeutics, Gilead Sciences
HIV/AIDS
10/22
12/22
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV

Active, not recruiting
2
60
US
VRX496-Modified Autologous T cells
VIRxSYS Corporation
HIV Infection
11/08
06/23
Rollover, NCT00622232: A Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial

Active, not recruiting
2
40
US
VRX496-transduced autologous CD4 T cells
VIRxSYS Corporation
HIV Infections
01/09
06/23
NCT00791700 / 2008-006873-33: An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

Active, not recruiting
2
103
Europe, US, RoW
Maraviroc, Selzentry
ViiV Healthcare, Pfizer
Human Immunodeficiency Virus
04/15
06/23
2015-001206-33: A pilot phase II study of a nucleoside sparing regimen of Dolutegravir + Atazanavir/r in HIV-1 infected patients with detectable viremia (Dolatav Study) Studio pilota, in aperto, sull'efficacia di un regime non contenente farmaci nucleosidici, con atazanavir/ritonavir associato a dolutegravir in pazienti con carica virale positiva (Studio Dolatav)

Not yet recruiting
2
40
Europe
Reyataz 300 mg, Norvir 100 mg, Tivicay, Reyataz 200 mg, A71IL, Capsule, hard, Film-coated tablet, REYATAZ - 300 MG CAPSULE RIGIDE - USO ORALE-FLACONE (POLIETILENE AD ALTA DENSITA') 30 CAPSULE, NORVIR - 100 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE(HDPE) 30 COMPRESSE, TIVICAY - 50 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, REYATAZ - 200 MG 60 CAPSULE IN BLISTER USO ORALE
OSPEDALE SAN RAFFAELE, Bristol-Myers Squibb S.r.l
HIV-1 infected patients pazienti affetti da virus HIV-1, pazienti affetti da infezione da HIV-1, Diseases [C] - Virus Diseases [C02]
 
 
LATTE-2, NCT02120352 / 2013-000783-29: A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Completed
2
309
Europe, Canada, US
CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
ViiV Healthcare, Janssen Pharmaceuticals, GlaxoSmithKline
Infection, Human Immunodeficiency Virus, HIV Infections
08/15
04/23
2015-003186-28: BIOSKILL: Studying Vacc-4x, an HIV therapeutic vaccine, an as-sessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the HDAC inhibitor, romidepsin

Ongoing
2
192
Europe
Vacc-4x, Leukine, Istodax, Vacc-4x, -, Powder for solution for injection, Powder and solution for solution for injection, Leukine, Istodax
Bionor Pharma ASA, Bionor Pharma ASA
HIV infection, HIV infection, Diseases [C] - Virus Diseases [C02]
 
 
2015-002955-85: A phase II feasibility study to assess changes in patients who have been identified as having cognitive function impairment following the addition of a new drug to an existing effective regime of three HIV antiretrovirals drugs

Ongoing
2
10
Europe
Cenicriviroc, TBR-652, Tablet
Imperial College London, Imperial College Healthcare NHS Trust Biomedical Research Centre
Human Immunodeficiency Virus, HIV, Diseases [C] - Virus Diseases [C02]
 
 
NCT02923713 / 2009-017013-29: TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Active, not recruiting
2
46
Europe, RoW
Darunavir, Ritonavir
Janssen Sciences Ireland UC, Janssen Medical Affairs,
HIV-1 Infections
06/17
06/17
 

Download Options